ArticleBMC pulmonary medicine2025
Clinical characteristic and prognosis of adult inpatients with high altitude pulmonary edema: a multi-central, retrospective study in plateau of China from 2012 to 2022.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHigh-altitude pulmonary edema (HAPE) is a common consequence of inadequate acclimatization to high altitude. However, there is currently limited evidence regarding the clinical characteristics and risk factors contributing to adverse outcomes in patients with HAPE.
methodsThis study enrolled 411 patients with HAPE from four hospitals in the plateau, between 2012 and 2022, and described their clinical characteristics. The relationship between the altitude of onset and the duration of stay in plateau and adverse outcomes was analyzed using restricted cubic splines. Stepwise logistic regression was conducted to investigate the risk factors for adverse outcomes in HAPE patients.
resultsThe risk of pulmonary hypertension in HAPE patients was positively associated with onset altitude, while the risk of pulmonary hypertension, thrombosis, high-altitude cerebral edema, and death was negatively related to duration of stay in plateau (P for overall association =0.029, P for nonlinear association =0.071). The multivariate logistic model showed that HAPE patients with onset altitude of ≥ 3,500 m, duration of stay in plateau ≤ 1-day, elevated lactic dehydrogenase and prolonged prothrombin time had a higher risk of pulmonary hypertension (OR = 0.42, 95% CI: 0.23–0.74). Patients with a history of hypertension and longer hospital stays had an increased risk of thromboembolism (OR = 6.71, 95% CI: 1.77–25.46). Fever (OR = 3.16, 95% CI: 1.17–8.55), headache (OR = 2.79, 95% CI: 1.37–5.65), and elevated blood urea nitrogen (BUN) levels (OR = 3.94, 95% CI: 1.93–8.04) were risk factors for high-altitude cerebral edema. Additionally, mortality risk was higher in patients with headache (OR = 2.11, 95% CI: 1.01–4.39), pulmonary hypertension (OR = 2.96, 95% CI: 1.08–8.13), high-altitude cerebral edema, and elevated BUN (OR = 5.26, 95% CI: 2.39–11.59) and N-terminal pro-brain natriuretic peptide levels (OR = 2.63, 95% CI: 1.20–5.78).
conclusionsOur findings indicate the importance of careful assessment and management of clinical indicators and risk factors in patients with HAPE, further to take effective early interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.